Beukelman T, et al. - Researchers ascertained if tumor necrosis factor inhibitor (TNFi) use was related to an increased rate of incident malignancy vs no TNFi use in the treatment of juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (pIBD) and pediatric plaque psoriasis (pPsO). An increased rate of malignancy was seen in children diagnosed with JIA, pIBD and pPsO vs the general population, but TNFi treatment seemed to have no significant impact on the risk, compared with no TNFi use.